Central Nervous System

Actinogen finishes enrolling patients in depression therapy trial

Australian biotechnology company Actinogen Medical has finished enrolling subjects in the Phase IIa XanaCIDD clinical trial of Xanamem for treating…

Cerevel reports positive data from Phase III Parkinson’s treatment trial

Cerevel Therapeutics has reported positive topline results from its Phase III TEMPO-3 clinical trial evaluating a once-a-day dose of tavapadon…

AAN 2024: new pooled data highlights efficacy of Axsome Therapeutics’s AXS-07

On 15 April, at the American Academy of Neurology (AAN) 2024, Axsome Therapeutics presented new pooled data from two Phase…

Hyperfine starts enrolment in portable imaging workflow study

US-based health technology company Hyperfine has enrolled the first patient in the clinical workflow study of its US Food and…

AAN 2024: AbbVie highlights long-term safety of atogepant in migraine prevention

At the American Academy of Neurology (AAN) 2024, AbbVie highlighted the long-term safety data of Qulipta (atogepant) for the preventive…

Bayer and AskBio report data from Parkinson’s disease therapy trial

Bayer and its subsidiary Asklepios BioPharmaceutical (AskBio) have reported data from an 18-month Phase Ib clinical trial of a gene…

Actinogen treats first subject in Alzheimer’s disease therapy trial

Australian biotechnology company Actinogen Medical has treated the first subject in the XanaMIA Phase IIb clinical trial of Xanamem in…

FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits

The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…

AviadoBio treats first subject in trial of FTD-GRN therapy

UK-based biotechnology company AviadoBio has administered its investigational gene therapy, AVB-101, to the first subject in the Phase I/II ASPIRE-FTD…

Teva’s Ajovy hits endpoint in Chinese Phase III trial for migraine prevention

Teva Pharmaceuticals has unveiled positive data from a Phase III study evaluating Ajovy (fremanezumab) for the prevention of migraines in…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close